Obefazimod for Crohn's Disease: A New Oral Drug Explained

If you have cycled through biologics and keep an eye on what might come next, you have probably seen obefazimod mentioned in IBD news. Obefazimod for Crohn's disease is a once-daily pill currently in a phase 2b trial, and the ulcerative colitis results behind the excitement are genuinely interesting. The part most coverage skips is that no Crohn's efficacy data has been published yet.

Many of us living with Crohn's have learned to read drug news carefully, because hope and evidence are not the same thing. Here is what is known, what is borrowed from a different disease, and what you can ask your IBD team about today.

Key Takeaways

• Obefazimod, formerly called ABX464, is a once-daily oral small molecule that selectively increases the microRNA miR-124 in immune cells, a different mechanism from anti-TNF, IL-23 or integrin drugs (1)
• As of November 2026, no efficacy results from an obefazimod Crohn's disease trial had been published in the peer-reviewed literature (4, 5)
• The Crohn's programme is a phase 2b randomised, quadruple-blind trial of 212 adults at 149 sites in 12 countries, begun on 30 October 2024 with primary completion estimated for December 2026 (4)
• In the phase 3 ABTECT-1 ulcerative colitis trial, week 8 clinical remission was reached by 21.7 percent on 50 mg and 23.8 percent on 25 mg versus 2.5 percent on placebo (2)
• Headache is the adverse event to know about: it affected 20.8 percent on 50 mg versus 5.7 percent on placebo in ABTECT-1 (2)
• Obefazimod is not approved by any regulator for Crohn's disease or ulcerative colitis, so there is no label, no price and no legitimate way to buy it (4, 6)

What Obefazimod Is and How It Works

Obefazimod, previously known as ABX464, is a once-daily oral small molecule that selectively increases expression of a single microRNA called miR-124 in immune cells (1). Instead of blocking one inflammatory messenger from the outside, it aims to turn up a regulatory brake the body already has. That makes it mechanistically distinct from every approved Crohn's biologic.

The miR-124 Mechanism in Plain Language

MicroRNAs are short pieces of genetic material that act as volume dials on gene activity. They do not build proteins themselves; they quieten the instructions for other proteins, including several that drive inflammation.

miR-124 is one of these dials, and in inflamed intestinal tissue it tends to be turned down. Obefazimod selectively upregulates it in immune cells (1). Rather than removing one cytokine from circulation, the drug nudges inflammatory signalling down across several pathways at once. Research published in The Lancet Gastroenterology and Hepatology described this as a novel approach for IBD (1), and whether a broader brake beats a precise block is exactly what the trials are built to answer.

How It Differs From Biologics and JAK Inhibitors

Anti-TNF drugs such as infliximab and adalimumab, IL-23 inhibitors such as risankizumab, and integrin blockers such as vedolizumab are all antibodies given by injection or infusion, and each targets one specific molecule. As we explored in our explainer on IL-23 inhibitors for Crohn's disease, that precision is a real strength, and also why losing response to one class pushes you toward another.

Obefazimod is a pill. For anyone counting needle burden, infusion appointments and travel, that difference is not cosmetic. It is closer in format to the JAK inhibitors, though not in mechanism, and our article on real-world results with JAK inhibitors in Crohn's disease covers how oral therapy has actually performed.

Worth stating plainly: obefazimod began as an antiviral candidate and was repurposed after anti-inflammatory effects were observed. That means the compound has been given to humans before. It does not mean its long-term safety in IBD is established.

Where the Obefazimod Crohn's Disease Evidence Stands Right Now

This is the section most news coverage leaves out. As of November 2026, no efficacy results from a Crohn's disease trial of obefazimod had been published in the peer-reviewed literature (4, 5). Everything circulating about how well it might work in Crohn's is extrapolated from ulcerative colitis, and that extrapolation has limits.

The Phase 2b Crohn's Trial

The Crohn's programme is a phase 2b randomised, quadruple-blind, placebo-controlled study testing 12.5 mg, 25 mg and 50 mg daily in 212 adults aged 18 to 75. It is running at 149 sites across 12 countries and began on 30 October 2024, with primary completion estimated for December 2026 (4).

Quadruple-blind means participants, investigators, care providers and outcome assessors are all unaware of assignment, which is why no interim numbers are drifting out.

The trial uses the Crohn's Disease Activity Index, or CDAI, for clinical response and remission, and the Simple Endoscopic Score for Crohn's Disease, known as SES-CD, for endoscopy (4). So the eventual readout will be a symptom score plus a direct look at whether the bowel lining has healed.

Why No Crohn's Efficacy Numbers Exist Yet

It is tempting to treat ulcerative colitis results as a preview, and in our community we have watched that assumption disappoint people before. Crohn's disease is transmural, meaning inflammation runs through the full thickness of the bowel wall and can appear anywhere from mouth to anus. Ulcerative colitis is mucosal and confined to the colon.

The endpoints differ too. Ulcerative colitis trials use the modified Mayo Score; Crohn's trials use CDAI and SES-CD, which are harder to move. Several therapies have worked in one disease and failed in the other.

Obefazimod is one of several new classes now in Crohn's trials, and our overview of TL1A inhibitors for Crohn's disease shows how uneven that pipeline can be. For the wider picture, see our roundup of new IBD treatments in 2026.

What the Ulcerative Colitis Trials Showed

The ulcerative colitis data is where obefazimod has a real track record: a phase 2b induction trial, a long open-label extension and a phase 3 programme. These results are why a Crohn's trial exists at all, so they are worth reading accurately.

Phase 2b Induction and Two-Year Follow-Up

The phase 2b induction trial randomised 254 patients with moderate-to-severe ulcerative colitis at 95 centres in 16 countries. At week 8, the least squares mean change in modified Mayo Score was -3.2 for the 50 mg dose versus -1.9 for placebo, with p=0.0003 (1).

Patients who continued into open-label maintenance were followed for two years. Of 217 patients on 50 mg daily, 164 (75.6 percent) completed week 96, with clinical remission in 114 (52.5 percent) and endoscopic remission in 78 (35.9 percent) (3). That completion rate is a signal in itself, because people generally stop drugs that are not working or not tolerable.

The Phase 3 ABTECT Programme

In the phase 3 ABTECT-1 induction trial, week 8 clinical remission was reached by 69 of 318 patients on 50 mg (21.7 percent), 38 of 160 on 25 mg (23.8 percent) and 4 of 158 on placebo (2.5 percent) (2). The placebo rate being that low makes the separation unusually clean.

Maintenance figures reported at week 44 showed clinical remission of roughly 51 percent on both doses versus 10 percent on placebo, and endoscopic remission of 41.5 percent on 25 mg and 47.7 percent on 50 mg versus 10 percent on placebo (6).

One honest caveat: those week 44 numbers come from company presentations and trade coverage rather than a peer-reviewed paper (6). Until they appear with full methods, they sit on a different evidence tier than the figures above.

Side Effects Reported So Far

Headache is the adverse event to know about. In ABTECT-1 it was the most common, affecting 66 of 318 patients (20.8 percent) on 50 mg, 25 of 160 (15.6 percent) on 25 mg and 9 of 158 (5.7 percent) on placebo (2).

Headache Is the Signal to Know About

A roughly fourfold increase over placebo at the higher dose is not trivial, and it appears dose-related. For most trial participants it was manageable rather than treatment-limiting, but if you already live with migraine, raise it specifically.

Serious adverse events in ABTECT-1 occurred in 14 of 318 patients (4.4 percent) on 50 mg, 1 of 160 (0.6 percent) on 25 mg and 3 of 158 (1.9 percent) on placebo (2). In the 96-week maintenance study the most frequent events were COVID-19 (14.3 percent), headache (11.5 percent), worsening colitis (7.8 percent) and nasopharyngitis (6.9 percent), with no new safety risks reported over two years (3).

What Has Not Been Seen

Because obefazimod is not approved anywhere, there is no regulatory label, no prescribing information and no boxed warning. That absence is not reassurance. The rare and long-term risks that only surface in tens of thousands of patient-years have not been characterised. Two years of open-label data is a good start and nothing more.

How It Might Fit Alongside Current Crohn's Treatments

If obefazimod is eventually approved, the realistic place for a new oral drug for Crohn's disease like this is alongside the JAK inhibitors, not as a replacement for biologics. Evidence indicates a novel mechanism, which matters most for people who have exhausted existing classes, but sequencing data does not exist yet.

No head-to-head trial against any approved Crohn's therapy has been run, so any comparison with risankizumab, ustekinumab, vedolizumab, adalimumab or upadacitinib would be guesswork.

There is also no price, no copay card and no patient assistance programme, because the drug is not marketed anywhere. If you find a website offering to sell obefazimod, it is not selling you obefazimod.

Approval would require positive phase 2b results, then full phase 3 Crohn's trials, then regulatory review. Availability and timing vary considerably by country, and even on a smooth path this typically adds years rather than months.

Should You Consider Joining a Trial?

If you have active Crohn's disease and have run short of options, a trial is a legitimate thing to ask about. As of November 2026 the phase 2b trial was recruiting in the United States, Belgium, Czechia, France, Germany, Hungary, Italy, the Netherlands, Poland, Romania, Slovakia and Spain (4).

Questions to Ask Your IBD Team

• Am I eligible given my disease location, previous therapies and current medication?
• Is there a participating site within realistic travel distance?
• What happens to my current treatment if I enrol, and what is the washout period?
• How many extra endoscopies and visits does participation involve?
• If I am randomised to placebo, what are the rescue criteria and the open-label extension options?

Where to Look Up Trial Sites

The trial record is on ClinicalTrials.gov as NCT06456593. Recruitment status and the site list change, so check the record directly rather than relying on an article, including this one.

Be clear-eyed about the trade-offs: a real chance of receiving placebo during induction, extra endoscopies, more frequent visits and symptom diaries. And if qualifying would mean stopping a therapy that is partly working, that carries genuine flare risk. The decision belongs with your gastroenterologist, who knows your disease history.

The Practical Takeaway

Obefazimod is one of the more interesting things in the IBD pipeline: a once-daily pill, a mechanism unlike anything approved, and ulcerative colitis data strong enough to justify a serious Crohn's programme. It is also a drug with no published Crohn's efficacy results, an uncharacterised long-term safety profile and years of regulatory work ahead.

Both are true at once. The phase 2b readout follows primary completion in December 2026, so this is a name worth keeping in view. For now it belongs on your list of questions, not your list of options.

Frequently Asked Questions

Is obefazimod approved for Crohn's disease?

No. As of November 2026, obefazimod was not approved by any regulator for Crohn's disease or ulcerative colitis, and the US new drug application for ulcerative colitis was described as planned rather than submitted (4, 6). It is available only through clinical trials, so any site offering to sell it is not legitimate.

Does obefazimod work for Crohn's disease?

Nobody knows yet. No efficacy results from a Crohn's trial have been published in the peer-reviewed literature (4, 5), and the phase 2b trial in 212 adults has an estimated primary completion of December 2026 (4). The positive results you may have read about are from ulcerative colitis trials, which do not automatically transfer to Crohn's.

How is obefazimod different from a biologic?

Two ways. It is a once-daily pill rather than an injection or infusion, and it works by increasing the microRNA miR-124 in immune cells rather than blocking a specific cytokine or receptor (1). Anti-TNF, IL-23 and integrin inhibitors each target one molecule precisely; obefazimod turns up a regulatory brake instead.

What are the side effects of obefazimod?

Headache is the most reported. In ABTECT-1 it affected 20.8 percent on 50 mg and 15.6 percent on 25 mg, versus 5.7 percent on placebo, and serious adverse events occurred in 4.4 percent on 50 mg versus 1.9 percent on placebo (2). Over 96 weeks, COVID-19, headache, worsening colitis and nasopharyngitis were most frequent, with no new safety risks identified (3).

Can I join the obefazimod Crohn's disease trial?

Possibly. The phase 2b trial was recruiting as of November 2026 across 149 sites in 12 countries, in adults aged 18 to 75 with moderately to severely active Crohn's disease (4). Eligibility depends on your disease activity and treatment history. Check the ClinicalTrials.gov record NCT06456593 for current status, then discuss it with your gastroenterologist.

Why do ulcerative colitis results not predict Crohn's results?

Crohn's inflammation is transmural, running through the full bowel wall and appearing anywhere in the digestive tract, while ulcerative colitis is mucosal and limited to the colon. The trials also use different endpoints: modified Mayo Score for ulcerative colitis, CDAI and SES-CD for Crohn's (4). Several IBD drugs have succeeded in one and failed in the other.

References

1. Vermeire S, et al. ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week open-label extension. The Lancet Gastroenterology and Hepatology, 2022. View on PubMed
2. Abivax. ABTECT-1: ABX464 Treatment Evaluation for Ulcerative Colitis Therapy-1 (NCT05507203), results posted. 2025. Read trial record
3. Danese S, et al. Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b study. 2025. View on PubMed
4. Abivax. Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease (NCT06456593). 2026. Read trial record
5. Obefazimod (ABX464) for moderate-to-severe Crohn's disease: clinical development of a novel oral therapeutic approach. 2026. View on PubMed
6. HCPLive. ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD. 2026. Read article